5-Aza-4'-thio-2’-deoxycytidine, a new orally bioavailable non-toxic “best-in-class”

DNMT1 depleting agent in clinical development

William B. Parker¹ and Jaideep V. Thottassery²

¹PNP Therapeutics, Birmingham, Alabama 35203 and ²UDG Healthcare, Smartanalyst - Ashfield Division, New York, NY 10017
Running Title page

Running Title:

5-Aza-4'-thio-2'-deoxycytidine, a new DNMT1 depleting agent

Corresponding Author
Jaideep V. Thottassery, PhD
Senior Director, Oncology,
UDG Healthcare,
Smartanalyst - Ashfield Division
285 Madison Ave, 22nd Floor,
New York, NY 10017
Tel: 212-331-0010
jthottassery1@icloud.com

Co-corresponding Author
William B. Parker
Founder
PNP Therapeutics
15 Richard Arrington Jr Blvd North
Birmingham, AL 35203
Tel: 205-937-6254
bparker@pnptherapeutics.com

Number of text pages: 21
Number of Tables: 1
Number of Figures: 7
Number of references: 113
Number of words in Abstract: 193
Total number of words (without references): 6082
Abbreviations:

AML: Acute myeloid leukemia
Aza-dCyd: 5-aza-2'-deoxycytidine (decitabine)
Aza-Cyd: 5-aza-cytidine (azacitidine)
Aza-T-dCyd: 5-aza-4'-thio-2'-deoxycytidine
CMML: Chronic myelomonocytic leukemia
Cyd: cytidine
dCyd: 2'-deoxycytidine
dThd: thymidine
dUrd: 2'-deoxyuridine
DNMT: DNA methyltransferase
F-dCyd: 5-fluoro-2'-deoxycytidine
HbF: fetal hemoglobin
MDS: Myelodysplastic syndromes
NCI: National Cancer Institute
PDX: Patient Derived Xenograft
T-dCyd: 4'-thio-2'-deoxycytidine
T-dThd: 4'-thio-thymidine
T-dUrd: 4'-thio-2'-deoxyuridine
THU: tetrahydouridine

Recommended section assignment: Drug Discovery and Translational Medicine
Abstract

DNA methyltransferase 1 (DNMT1) is an enzyme that functions as a maintenance methyltransferase during DNA replication, and depletion of this enzyme from cells is considered to be a rational goal in DNA methylation dependent disorders. Two DNMT1 depleting agents aza-dCyd (5-aza-2'-deoxycytidine, decitabine) and aza-Cyd (5-aza-cytidine, azacitidine) are currently used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, and have also been investigated for non-oncology indications such as sickle cell disease. However, these agents have several off-target activities leading to significant toxicities that limit dosing and duration of treatment. Development of more selective inhibitors of DNMT1 could therefore afford treatment for long durations at effective doses. We have discovered that 5-aza-4'-thio-2'-deoxycytidine (aza-T-dCyd) is as effective as aza-dCyd in depleting DNMT1 in mouse tumor models, but with markedly low toxicity. In this review we describe the preclinical studies that led to the development of aza-T-dCyd as a superior DNMT1 depleting agent with respect to aza-dCyd, and will describe its pharmacology, metabolism, and mechanism of action. In an effort to understand why aza-T-dCyd is a more selective DNMT1 depleting agent than aza-dCyd, we will also compare and contrast the activities of these two agents.

Significance Statement.

Aza-T-dCyd is a potent DNMT1 depleting agent. Although similar in structure to decitabine (aza-dCyd) its metabolism and mechanism of action is different than that of aza-dCyd, resulting in less off target activity and less toxicity. The larger therapeutic index of aza-T-dCyd (DNMT1 depletion vs toxicity) in mice suggests that it would be a better clinical candidate to selectively deplete DNMT1 from target cells and determine whether or not depletion of DNMT1 is an effective target for various diseases.
Introduction: DNA hypomethylation using DNMT1 depleting nucleosides

Methylation of cytosines in DNA occurs mainly in the context of CG dinucleotides that are distributed throughout the genome, including within repetitive sequences, enhancers, promoters, and coding regions (Robertson, 2005; Du et al., 2015; Ramsahoye et al., 2000). Cytosine methylation is mediated by a family of enzymes known as the DNA methyltransferases (DNMTs), which catalyze the transfer of a methyl group from S-adenosylmethionine to the 5 position of cytosine residues in DNA. DNMT1, which is the most abundant DNMT, is a maintenance methyltransferase that methylates the newly replicated strand and preserves the existing methylation pattern in DNA, while DNMT3A and DNMT3B largely establish methylation patterns de novo on previously unmethylated DNA (Du et al., 2015). DNA methylation of DNA results in transcriptional silencing by regulating formation of heterochromatin (Bachman et al., 2001) and influencing the accessibility of transcription factors to DNA. Methylated CGs can regulate transcription factor binding and also affect transcription by recruiting methyl-CG binding proteins that affect chromatin structure through interactions with other proteins such as those that modify histones (Hendrich and Bird, 2000; Ragione et al., 2016).

DNA methylation must be actively maintained in every replication cycle by DNMT1 and can therefore be reversed by inhibition or depletion of the enzyme. Several DNA hypomethylating nucleosides have been evaluated in the clinic and two of these agents aza-dCyd (5-aza-2'-deoxycytidine, decitabine) and aza-Cyd (5-aza-cytidine, azacitidine) (Figure 1)) have been approved by the FDA for the treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Treatment with either of these agents results in the incorporation of aza-cytosine in place of cytosine in DNA. DNMT1 gets covalently trapped when it attempts to methylate aza-cytosines that are diagonally opposite a 5-methylcytosine in the template strand. The covalent complex thus effectively reduces the availability of active DNMT1
and also induces proteasomal degradation of the free enzyme (Santi et al., 1984; Ghoshal et al., 2005; Patel et al., 2010). Although active against heme malignancies, these agents are much less effective in solid tumors. Both agents have poor oral bioavailability, poor stability due to hydrolytic cleavage of the triazine ring, and considerable toxicity.

5-fluoro-2’-deoxycytidine (F-dCyd, Figure 1), a stable nucleoside, was shown in early studies to be active in solid tumor models as well as in leukemias (Mukherjee and Heidelberger, 1962; Eidinoff et al., 1959). Like aza-dCyd, F-dCyd is activated via dCyd kinase to F-dCTP, which is readily incorporated into DNA. It was later recognized to inhibit methylation in cells and was shown to induce expression of tumor suppressor genes such as p16/CDKN2A (Jones and Taylor, 1980; Kaysen et al., 1986; Osterman et al., 1988; O’Sullivan Coyne et al., 2020). Because of the fluorine in the 5-position of the pyrimidine ring, DNMT1 forms a covalent complex with DNA, which causes its subsequent depletion. However, F-dCyd has a serious toxicity problem because it is readily converted via both Cyd deaminase and dCMP deaminase (Figure 2) (Newman and Santi, 1982; Boothman et al., 1985) to 5-F-2’-deoxyuridine-5’-phosphate (F-dUMP), a potent inhibitor of thymidylate synthase (Parker and Cheng, 1990). Therefore, F-dCyd is not a selective DNMT1 depleting agent. F-dCyd was tested in patients in combination with tetrahydrouridine (THU), a potent inhibitor of Cyd deaminase, in an effort to enhance formation of F-dCMP (Holleran et al., 2015; Beumer et al., 2008, Beumer 2008a). However, recently reported results in different solid tumor patient cohorts have demonstrated very low response rates (O’Sullivan Coyne et al., 2020).

Zebularine ([1-((β-D-ribofuranosyl)-1,2-dihydropyrimidin-2- one], Figure 1) is another stable cytidine analog, which is an inhibitor of DNA methylation with improved oral bioavailability. Once incorporated into DNA this agent also forms covalent complexes with DNMT1 resulting in
its depletion, the reactivation of previously hypermethylated tumor suppressor genes, and
antitumor activity in various mouse models (Yoo et al., 2008). However, it is a riboside analog
and was found to have poor potency against DNMT1 owing to its limited incorporation into DNA
(Ben-Kasus et al., 2005). Zebularine’s weak conversion to 2’-deoxynucleotide metabolites, and
the inability of 2’-deoxyzebularine to be phosphorylated to its active metabolite resulted in the
discontinuation of this line of investigation.

Recently other DNMT1 depleting nucleosides such as guadecitabine (SGI-110 or S-110) and
NUC013 have also entered development. Guadecitabine is a dinucleotide of aza-dCyd linked
via a phosphodiester to deoxyguanosine, which was developed as a stable prodrug of aza-dCyd
that is also less vulnerable to deamination by Cyd deaminase (Roboz et al., 2018). However,
there have been two recent phase III failures with this drug when it was tested in MDS, AML
and CMML (NCT02920008, NCT02907359). NUC013 (5-aza-2’,2’-difluoro-2’-deoxycytidine) is
another aza-nucleoside that decreases DNMT1 levels and has shown efficacy in xenograft
models of human leukemia and colon cancer (Daifuku et al., 2017). However, since this
compound is an analog of gemcitabine (2’,2’-difluoro-2’-deoxycytidine), it is expected to induce
chain termination during replication resulting in off target activities. NUC013 and its prodrug
NUC041 have therefore not moved beyond preclinical development stages (Daifuku et al. 2017,
2018).

**DNMT1 depletion and treatment of solid tumors.**

Diseases such as cancer, where hypermethylation of CG regions play a role in their
development, could theoretically be treated with agents that induce the proteolytic degradation
of DNMT1. Since cells with reduced or absent DNMT1 are able to complete replication,
hypermethylated tumor suppressor genes are demethylated and re-expressed in subsequent
generations, which leads to eventual growth inhibition and or apoptosis in cancer cells within 1-2
replication cycles. Several preclinical studies in solid tumors have shown that treatment with DNA hypomethylating agents can synergize with, or restore sensitivity to, chemotherapies, targeted agents (Anzai et al., 1992; Soengas et al., 2001; Hou et al., 2019), and very recently even immune checkpoint agents (Yu et al., 2019; Huang et al., 2020; Gonda et al., 2020). The biological basis of these effects was consistent with a number of reports that had demonstrated 1) reversal of hypermethylation of CG islands in tumor suppressor genes, 2) epigenetic immunomodulation by these drugs, and 3) the role of DNMT1 overexpression in tumorigenesis (Merlo et al., 1995; El-Deiry et al., 1991; Coral et al., 1999). The importance of DNMT1 overexpression had not only been recognized in early studies where it was shown to increase proliferation and induce transformation (Wu et al., 1993), but was further strengthened by the observation that it correlates well with metastasis, poor prognosis, and aberrant methylation in several solid tumor patient cohorts (Saito et al., 2003; Zhao et al., 2011, Peng et al., 2006, Yuan et al., 2016). Consistent with these studies, several reports had also demonstrated that depletion of DNMT1 by siRNA approaches can inhibit growth of tumor cells both \textit{in vitro} and \textit{in vivo} (Xiang et al., 2014; Milutinovic et al., 2004; Milutinovic et al., 2000). A systematic meta-analysis of 58 clinical studies of DNA hypomethylating drugs concluded that while these drugs improved outcome and altered methylation status in solid tumor patients, overall response was limited (Linnekamp et al., 2017). Despite the plethora of clinical trials that have investigated DNA hypomethylators none of these drugs have been approved for solid tumors. One major reason that had been suggested is the limited number of treatment cycles in these studies with these drugs, often due to toxicities, and given that delayed responses were seen in a number of patients, long treatment durations would be necessary to achieve clinical benefit.

**DNMT1 depletion and hemoglobinopathies.**

Initial empirical observations had demonstrated that antileukemic effects of aza-dCyd were accompanied by irreversible hemoglobinization and morphological differentiation in
erythroleukemic cells (Pinto A et al., 1983). These observations coupled with the knowledge that the expression of $\gamma$-globin (HbF or fetal hemoglobin) is associated with the status of its CG methylation in the adult (van der Ploeg and Flavelle, 1980, Mavilio et al., 1983), spurred the extension of aza-nucleoside studies into hemoglobinopathies such as sickle cell disease and thalassemia (Charache PNAS 1983; Desimone et al., 1982). DNMT1 by interacting with transcriptional regulators like Myb and Bcl11A, has been shown to be required to maintain HbF silencing (Xu et al., 2013). The role of DNMT1 also appears to involve methylation of promoters of other HbF gene modifiers (e.g. ZBTB7) (Roosjen et al., 2014; Chondrou et al., 2018). Inhibition of DNMT1 activity by aza-dCyd, aza-Cyd or guadecitabine has been shown to enhance HbF expression in primary erythroid cells, non-human primates and in humans (Desimone et al., 1982; Humphries et al., 1985; Lavelle 2010; Lavelle et al., 2018; Stomper and Lubbert, 2019). This led to clinical trials where aza-dCyd was shown to successfully induce HbF in patients with sickle cell disease intolerant to hydroxyurea and in $\beta$-thalassemia (Saunthararajah et al., 2003; Olivieri et al., 2011; Saunthararajah et al., 2019). While this provided clinical proof-of-concept that subcutaneous administration of low-dose aza-dCyd increases HbF, Molokie et al. (2017) decided to provide an oral route of administration by combining the drug with THU to inhibit intestinal and liver Cyd deaminase. This small randomized study concluded that twice weekly low dose aza-dCyd (5 mg/m$^2$ versus the approved i.v. 5-day dose of 20 mg/m$^3$) when combined orally with THU achieved the pharmacokinetic objectives of low Cmax with long half-life/Tmax and the pharmacodynamic objectives of DNMT1 depletion, DNA hypomethylation, increase in HbF, and an increase in numbers of healthy red blood cells. Since this was a first-in-human study of this combination with a small number of patients for only 8-weeks, it is unknown whether this will translate into long-term clinical benefits in terms of reducing veno-occlusive events, associated morbidities, and low life spans. However, an oral toxicity study in mice that evaluated the THU and aza-dCyd combination did show increased toxicity as compared to aza-dCyd alone, which
suggested that the trade-off for improved oral pharmacokinetics might be increased adverse events (Terse et al., 2014).

**Off target activities of DNA hypomethylating nucleosides.**

What is the evidence that clinically used DNA hypomethylating nucleosides could be exerting their pharmacological and/or toxic effects at least in part by employing alternative mechanisms?

First and foremost, DNMT1 inhibition *per se* is relatively non-toxic to cells. An orally bioavailable non-nucleoside DNMT1 inhibitor has been shown to induce HbF levels in primary human erythroid cells equivalent to that induced by aza-dCyd, but with little cellular growth inhibition and had good tolerability in transgenic SCD mice (Gilmartin et al., 2020). In contrast, as described in greater detail below, aza-dCyd is a known cytotoxic nucleoside analog. Aza-dCyd induces genome-wide DNA damage and cytotoxicity arising from the DNA - DNMT1 cross-links which can block DNA synthesis and induce directly or indirectly DNA double-strand breaks, eventually leading to cell death (Palii et al., 2008; Juttermann et al., 1994). Aza-dCyd has also been reported to induce point mutations and genome rearrangements most likely due to protein–DNA cross-links (Maslov et al., 2012; Jackson-Grusby et al., 1997). It is well established that aza-dCyd treatment induces the activation of a specific DNA damage response that includes the phosphorylation of histone H2AX (Palii et al., 2008; Wilsker et al., 2019). Recently, it has also been proposed that base excision repair might initiate the repair of aza-dCyd induced DNA base lesions, although the precise mechanisms and the DNA glycosylases involved remains unknown (Orta et al., 2014). Lastly, an alternative mechanism for aza-dCyd in which its metabolism ultimately leads to the genotoxic accumulation of dUTP in the cellular pool has also been demonstrated (Requena et al., 2016). In the case of aza-Cyd, in addition to toxicities associated with its metabolism to aza-2'-deoxynucleotides, it is also impaired by those stemming from its incorporation into RNA (with the RNA:DNA incorporation ratio being 65:35) (Hollenbach et al., 2010; Cheng et al., 2018). Given the above considerations with approved
DNA hypomethylating drugs and the potential for leveraging the benefits of long-term depletion of DNMT1 it is imperative to identify newer and more selective DNMT1 depleting agents that exhibit less toxicity.

**Design of novel 4’-thio-2’deoxycytidine agents.**

The design of new nucleoside analogs targeting DNMT1 must recognize that sequential intracellular steps that lead to DNA incorporation and strand elongation need to be efficient: i.e. modifications in the nucleoside should not: 1) impede activation to the triphosphate and incorporation into DNA, 2) inhibit extension of the DNA chain after incorporation, or 3) prevent extrusion of the base from the double helix and/or binding to the active site of DNMT1. In addition, any new agent (or its metabolites) should not inhibit other enzymes that are involved in nucleotide metabolism (Figure 2). In our studies (Parker et al., 2000; Thottassery et al., 2014), we have evaluated 4’-thio-2’-deoxycytidine (T-dCyd) and its 5-aza analog (aza-T-dCyd) (Figure 1) and found that they fulfil many of the requirements described above. T-dCyd is readily phosphorylated and incorporated into DNA, and the 4’-thio modification to 2’-deoxycytidine (dCyd) alters metabolism in a positive manner resulting in relatively little production of 2’-deoxyuridine (dUrd) or thymidine (dThd) nucleotide metabolites in human cells.

In this work we review the development and rationale for use of aza-T-dCyd as a DNMT1 depleting agent, which we have discovered is as effective as aza-dCyd in depleting DNMT1 but with much less toxicity. In addition, we will compare and contrast its biochemical pharmacology and mechanism of action with aza-dCyd in an effort to understand why aza-T-dCyd is a more selective DNMT1 depleting agent. For the purposes of this review we have restricted the comparison of aza-T-dCyd to aza-dCyd, since aza-Cyd is a ribonucleoside and its off-target activities result from its incorporation into RNA in addition to its effects after conversion to deoxynucleotide metabolites.
Metabolism and depletion of DNMT1 by T-dCyd

Previously we have thoroughly evaluated the metabolism of T-dCyd in cells in culture (Parker et al., 2000; Thottassery et al., 2014), which provides insight into the effect of a 4'-thio group on the metabolism of dCyd and dUrd nucleosides and nucleotides (Figure 3). In CCRF-CEM cells (a cell line that does not express Cyd deaminase) T-dCyd was readily routed through dCyd kinase but was not converted to dThd nucleotides since T-dCMP is at best a poor substrate for dCMP deaminase (Parker et al., 2000). In stark contrast to the predominant conversion of dCMP to dUMP (Figure 2) in these cells when incubated with dCyd, no T-dUMP was formed from T-dCyd (Figure 3). The T-dCTP formed from T-dCyd was readily incorporated into DNA without inhibition of DNA replication (Parker et al., 2000). Therefore, its cytotoxicity in CEM cells is due to some disruption of DNA function once incorporated into the DNA chain. 4'-Thio-thymidine (T-dThd) is also a potent cytotoxic compound that, like T-dCyd, is readily phosphorylated in cells and incorporated into DNA without inhibiting DNA replication (Parker et al., 1995). Therefore, the cytotoxicity resulting from treatment with either of these 4'-thio-deoxy nucleosides is due to some disruption of DNA function once incorporated into the DNA chain.

In HCT-116 cells (a human colon carcinoma cell line that expresses high levels of cytidine deaminase) T-dCyd was mostly converted to T-dUrd (Thottassery et al., 2014), which indicated that T-dCyd was a good substrate for Cyd deaminase (Figure 3). The addition of Cyd deaminase inhibitor, THU, to cells treated with T-dCyd totally inhibited the formation of T-dUrd, but in these short-term experiments had very little effect on the incorporation of T-dCyd into DNA or the level of T-dCTP. The catalytic efficiency of T-dCyd with Cyd deaminase in crude cell extracts from HCT-116 cells was approximately 50% that of dCyd with a $K_m$ that was ~5 times that of dCyd (110 vs 23 μM) and a $V_{max}$ which was ~3 times that of dCyd (37 vs 13
nmol/mg-min). Although most T-dCyd was converted to T-dUrd, there was little evidence that T-dUrd was phosphorylated by dThd kinase and then converted to T-TMP via thymidylate synthase: 12% of dCyd was converted to dThd nucleotides in HCT116 cells, however, only 0.2% of T-dCyd was converted to T-dThd nucleotides. This observation supports previous studies (Secrist et al., 1991; Verri et al., 2000) that indicated T-dUrd was a poor substrate for dThd kinase. In addition, T-dUrd was not a substrate for dThd phosphorylase in crude cell extracts of HCT-116 cells [unpublished observation].

Pharmacokinetic studies in mice support the observation that T-dUrd is at best a poor substrate for dThd phosphorylase. After IP administration T-dCyd was primarily converted to T-dUrd and a major metabolite detected in mice treated with dCyd (presumably uracil and/or its catabolites) was not detected in the plasma after administration of T-dCyd (Thottassery et al., 2014). T-dUrd was also the primary circulating metabolite in pharmacokinetic studies conducted by investigators at the NCI (Kinders et al., 2014). The half-life of T-dCyd after IV or IP administration in mice was on the order of 10 to 15 minutes, whereas the plasma concentration of T-dUrd was stable for up to 4 hours at levels similar to those of the peak concentration of T-dCyd. A small amount of T-dThd was also detected in plasma (500-fold less than T-dUrd), which indicated that T-dUrd could be phosphorylated and converted to T-TMP via thymidylate synthase.

In summary, the metabolic studies described above indicated that T-dCyd metabolites (T-dCMP and T-dUrd) are at best poor substrates for dCMP deaminase, dThd kinase, and dThd phosphorylase (Figure 3), which significantly reduces the amount of dThd metabolites created in human cells after treatment with T-dCyd. The understanding that T-dCTP and T-TTP do not inhibit DNA replication (Parker et al., 2000; Parker et al, 1995) and structural studies (Kumar et al., 1997), which indicated that T-dCyd could inhibit methylation by Hhal methyltransferase, led
us to consider T-dCyd as a novel agent for DNMT1 depletion. Since dUrd and dThd metabolites of T-dCyd (T-dUMP, T-TTP, others) would not contribute to the inhibition of DNMT1 activity and could only contribute to toxicity of the compounds, we hypothesized that T-dCyd could be a much more selective agent in its ability to deplete DNMT1 in human cells.

Although T-dCyd was able to deplete DNMT1 from tumor cells in vivo and in vitro (Thottassery et al., 2014), its ability to do so was not universal in vitro and was only effective in mice at high concentrations, which were near its maximally tolerated dose. In addition, because T-dCyd is a good substrate for Cyd deaminase and a poor substrate for dThd phosphorylase, the primary circulating metabolite of T-dCyd in mice was T-dUrd (Kinders et al., 2014). Moreover, the detection of T-dThd in the plasma of mice indicated that T-dUMP is a substrate for thymidylate synthase and that T-dThd nucleotides were formed in mouse tissues. Although only a small amount of T-dThd was detected in plasma, our previous studies with this compound (Parker et al., 1995) indicated that it is readily incorporated into DNA and is not removed by proof reading enzymes. Therefore, the bulk of T-dThd nucleotides formed in cells would be sequestered in the DNA in the time frame of the pharmacokinetic studies. These results suggest that due to the long plasma half-life of T-dUrd the primary target responsible for in vivo antitumor activity of T-dCyd was the incorporation of T-TTP into DNA, which would not contribute to DNMT1 depletion. Toxicity associated with the incorporation of T-dThd into DNA would likely interfere with T-dCyd depletion of DNMT1. In support of this conclusion, studies done by the NCI (unpublished observation) indicated that treatment with T-dUrd resulted in excellent antitumor activity in the NCI-H23 mouse xenograft model, and that addition of THU to T-dCyd treatment resulted in decreased antitumor activity. This result suggests that the antitumor activity seen with T-dCyd is primarily due to metabolites of T-dUrd.
T-dCyd in first-in-human clinical trial

Following successful demonstration of efficacy in preclinical tumor xenografts in mice the NCI developed the analytical assays for T-dCyd (Liu et al., 2016), prepared an IND, and began a first-in-human open label Phase I trial with T-dCyd (O’Sullivan et al., 2016). Subjects were solid tumor patients whose disease had progressed on standard therapy. The primary objective was to establish the safety, tolerability, maximal tolerated dose, and recommended phase II dose. The study had entered dose level 5 enrollment, but recruitment has been suspended, presumably due to lack of clinical activity at nontoxic doses.

Development of aza-T-dCyd.

Because of the above considerations with T-dCyd, we turned our attention to aza-T-dCyd, which is structurally similar to aza-dCyd (Figure 1). The in vitro cytotoxicity of aza-T-dCyd was 3 to 4-fold more potent than T-dCyd in various human tumor cells (Teicher et al., 2019) and was also 10-fold more potent than aza-dCyd in HCT-116 cells (Laranjeira et al., 2017). Experiments were conducted to compare the cytotoxicity of aza-T-dCyd and aza-dCyd in HCT116 parental cells and an isogenic HCT116 cell line in which the DNMT1 gene had been knocked out (Laranjeira et al., 2017). The DNMT1 knockout HCT116 cells were 300-fold less sensitive to aza-T-dCyd (96 hours of drug exposure), whereas these cells were only 10-fold less sensitive to aza-dCyd. These results are consistent with the suggestion that off-target activities of aza-dCyd contribute more to its cytotoxic activity than they do to the cytotoxic activity of aza-T-dCyd.

Treatment of mice bearing CEM xenografts with either aza-T-dCyd or aza-dCyd resulted in the depletion of DNMT1 from the tumor cells (and supposedly any host cell that was replicating during this period). However, aza-dCyd was much more toxic to the mice than aza-T-dCyd (Table 1). In another experiment (Figure 4) mice bearing subcutaneous CEM tumor xenografts were treated with either 1 mg/kg aza-T-dCyd or 0.5 mg/kg aza-dCyd daily for 9 days to
determine what effect these compounds had on tumor growth. Aza-dCyd had no effect on tumor growth during the 9-day treatment period and resulted in the death of all mice. Aza-T-dCyd did inhibit tumor growth modestly but importantly, did not result in any weight loss or death of the mice. Therefore, after a 3-day rest period treatment was resumed for another 20 days also without weight loss or death of mice. As seen above, DNMT1 was undetectable in tumor cells at the end of the 20-day treatment. This result demonstrates that aza-T-dCyd effectively depletes DNMT1 in tumor cells \textit{in vivo} at doses that were very well tolerated by the mice.

In a subsequent experiment (unpublished) mice were treated with either 1 or 2 mg/kg aza-T-dCyd daily for 20 days. The low dose again had a small impact on tumor growth, but the high dose resulted in excellent antitumor activity, although at this dose there were 3 deaths (out of 8 treated mice) that may have resulted from the therapy (all deaths occurred shortly after treatment ended). In theory, depletion of DNMT1 should not be acutely cytotoxic to tumor cells but should instead slow tumor growth due to re-expression of tumor suppressor genes. In support of this we have demonstrated that the tumor suppressor genes p15/CDKN2B (Thottassery et al., 2014) and p16/CDKN2A (unpublished) are re-expressed in aza-TdCyd treated cells. Therefore, it is likely that the antitumor activity seen with high doses is due to off target activity of aza-T-dCyd, unlike that seen at low doses. Regardless, the experiments suggest that depletion of DNMT1 in host tissues is not toxic and that any off-target activities and toxicities of aza-T-dCyd occur at doses that are well above those needed to deplete DNMT1. Because the therapeutic index of aza-T-dCyd (DNMT1 depletion vs toxicity) is large, our \textit{in vivo} results in mouse models of cancer indicate that mice can be treated with aza-T-dCyd on an extended schedule at non-toxic, DNMT1 depleting doses, which would allow for treatment of all target cells as they enter S phase.
Antitumor activity of aza-T-dCyd.

We demonstrated that aza-T-dCyd was very effective in inducing growth inhibition in NCI-H23 lung tumor xenografts (Thottassery et al., 2014). Studies conducted at the NCI (unpublished observation) showed that, unlike T-dCyd, addition of THU to aza-T-dCyd treatment enhanced the antitumor activity of aza-T-dCyd, suggesting that deamination of this compound resulted in inactive metabolites. In HL-60 leukemia xenografts, treatment with either aza-T-dCyd alone or aza-T-dCyd in combination with THU resulted in significant tumor growth inhibition (Nguyen et al., 2016), which was associated with simultaneous inhibition of DNMT1 and DNMT3B. Interestingly, the tumor growth delay in mice treated with aza-T-dCyd plus THU was less than that seen in mice treated with only aza-T-dCyd. Treatment with aza-dCyd did not result in tumor growth delay in HL-60 leukemia xenografts even though both DNMT3A and DNMT1 levels were decreased. Treatment of mice with aza-dCyd or aza-T-dCyd along with isotopically labeled methionine resulted in a reduction in the enrichment of methyl-deoxycytidine in DNA by 20 to 70% in tumor tissue, bone marrow, and intestine (Anderson et al., 2017), which supported the observation that treatment with these compounds results in the depletion of DNMT1 in various tissues.

Aza-T-dCyd was also evaluated in comparison with T-dCyd in pediatric acute lymphoblastic leukemia (ALL) patient derived xenograft (PDX) models in order to assess their potential in hematological malignancies. Treatment with aza-T-dCyd showed impressive remission-inducing activity for ALL xenografts and was, in general, more active than T-dCyd (Teicher et al., 2019; Teicher et al., 2018). Profound responses were observed across a range of ALL biology, including: B-ALL (ALL-2, ALL-7, ALL-19), T-ALL (ALL-8, ALL-31), early T-cell phenotype (ETP) ALL (ETP-1), MLL-rearranged infant ALL (MLL-7), and Ph-like ALL (PAKHZT). T-dCyd and aza-T-dCyd were also tested in PDX models of Ewing sarcoma, rhabdoid tumor, rhabdomyosarcoma, and osteosarcoma. At tolerable doses, the anticancer activity of both T-
dCyd and aza-T-dCyd were found to be modest in the Ewing sarcoma (4) and rhabdomyosarcoma (4) models. The activity of both compounds was also modest in 5 out of 6 osteosarcoma models. However, the median survival of mice bearing the OS-9 osteosarcoma doubled (42 days) upon treatment with T-dCyd and increased nearly 4-fold (84 days) in mice treated with aza-T-dCyd (Teicher et al., 2019; Teicher et al., 2018). Neither aza-T-dCyd nor T-dCyd were active against pediatric brain tumor xenografts. In these studies, there was moderate correlation between expression of DNMT1 and the antitumor activity of aza-T-dCyd. Although toxicity was observed, treatment with aza-T-dCyd (1 to 2 mg/kg daily x 5 repeated weekly for 3 or 4 weeks) resulted in impressive remissions in acute lymphocytic leukemia xenografts (Teicher et al., 2018). Aza-T-dCyd was not active against solid tumor xenografts, although it did prevent growth of two sarcoma xenografts. T-dCyd was not active in these tumor models. Treatment with T-dCyd, but not aza-T-dCyd, resulted in significantly advanced overall survival associated with hematological improvement in an *in vivo* model of myelodysplastic syndrome (Khawaja et al., 2018), although aza-T-dCyd was toxic at the selected dose (4 mg/kg/day on weekdays for 2 weeks repeated after 21-day rest).

Recently Morris et al (2021) have described the antitumor activity of 2'-fluoro-5-aza-4'-thio- 2'-deoxy-arabinofuranosyl cytosine (F-aza-T-dCyd) and compared its *in vitro* and *in vivo* activity with aza-T-dCyd. Interestingly, there was a low COMPARE correlation between these two compounds in the 2-day NCI-60 assay, which suggested that the mechanism of action of these two compounds is different. Studies with clofarabine (2-chloro-2'-fluoro-2'-deoxy-arabinofuranosyl adenine, a molecule that like F-aza-T-dCyd has a fluorine atom at the 2' position) indicate that addition of F at this position in an arabinose configuration results in potent inhibition of DNA polymerase once converted to the triphosphate (Parker et al., 1991; Parker et al. 1999). Therefore, it is likely that the mechanism of action of F-aza-T-dCyd involves inhibition of DNA replication more so than aza-T-dCyd.
Pharmacokinetics of aza-T-dCyd

Studies conducted at the NCI indicate that the oral bioavailability of aza-T-dCyd in mice (2 mg/kg) was 80% of that seen after IV administration (unpublished observation). Studies by Momparler indicated that the oral bioavailability of aza-dCyd was only 9% (Momparler, 1985). The low oral bioavailability of aza-dCyd in nonhuman primates could be improved by pretreatment with THU, which indicated that Cyd deaminase activity contributed to its poor bioavailability (Lavelle et al., 2012), and there are now oral formulations for administering aza-dCyd to humans. The high oral bioavailability of aza-T-dCyd suggests that this compound may be a poor substrate for Cyd deaminase. It is also possible that the rapid decomposition of aza-dCyd contributes to its poor oral bioavailability (Momparler, 1985). We have shown that the half-life of aza-T-dCyd in phosphate buffer at pH 6.2 is approximately 5 times that of decitabine (Thottassery et al., 2014), which suggests that the increased chemical stability of this compound could contribute to its good oral bioavailability.


Based on the good antitumor activity of aza-T-dCyd observed in mouse xenografts, the NCI initiated a phase I clinical trial, which is ongoing (Monge et al., 2019, Nguyen et al. 2021). In this trial aza-T-dCyd is administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles. As of January 2021 (Nguyen et al. 2021), a total of 18 patients with solid tumors have been enrolled in the trial and a maximal tolerated dose of 32 mg has been determined. Of 14 patients that were evaluable for response, 11 had a best response of stable disease, and 3 had a best response of progressive disease. The median cycles of therapy was 4, and one patient with clear cell ovarian carcinoma has been on study for 10+ cycles (30+ weeks). The authors concluded that aza-T-dCyd is safe and well tolerated with a toxicity profile similar to currently approved hypomethylating agents. Global DNA methylation profiling,
RNAseq, and DNMT immunohistochemical analyses of tumor biopsies are planned for the currently accruing dose expansion cohort.

**Comparison of the metabolism and activity of aza-T-dCyd and aza-dCyd.**

Although aza-dCyd has been studied for many years (Momparler, 2005), there is still much that is not known about its mechanism of action, and a brief review of its activity may be useful to understand how aza-T-dCyd could differ from aza-dCyd and possibly suggest reasons for their different toxicity profiles. The enzymes involved in the metabolism and activity of aza-dCyd are shown in Figure 5. In *in vitro* studies it is clear that aza-dCyd is readily activated to aza-dCTP, which is incorporated into DNA resulting in the depletion of DNMT1. Aza-dCyd is a good substrate for dCyd kinase (Momparler and Derse, 1979; Cihak et al., 1980; Vesely and Cihak, 1980; Vesely, 1987), which is the rate limiting enzyme in the activation of most deoxynucleoside analogs. It has also been shown to be a good substrate for DNA polymerase α (Bouchard and Momparler, 1983; Vesely and Cihak, 1977), one of the primary DNA polymerases responsible for DNA replication, without causing chain termination.

It is known that aza-dCyd is a reasonably good substrate for Cyd deaminase (Chabot et al., 1983; Laliberte et al., 1992), and most of aza-dCyd that is administered to an animal is converted to 5-aza-2’-deoxyuridne (aza-dUrd) (Lavelle et al., 2012; Ebrahem et al., 2012). The $K_m$ for aza-dCyd was 10 to 20-fold that of dCyd, but its $V_{max}$ was similar. Aza-dCMP is also a substrate for dCMP deaminase (Momparler et al., 1986; Momparler et al., 1984), which creates aza-dUMP. Although in this case the $K_m$ of aza-dCMP was similar to that of dCMP, but its $V_{max}$ was only 1% that seen with dCMP. *In vivo* studies (Terse et al., 2014) showed that treatment of mice with THU plus aza-dCyd was more toxic to mice than treatment with aza-dCyd alone, and that the increased toxicity correlated with increased aza-dCyd plasma levels. These results suggest that the toxicity of aza-dCyd in mice is primarily due to its conversion to aza-dCMP.
However, THU does not inhibit dCMP deaminase activity and deamination of aza-dCMP could still produce considerable amounts of aza-dUMP in cells. Our studies with CEM cells (Parker et al., 2000) indicate that 90% of dCMP formed in cells is deaminated to form dUMP and it is possible that much of the aza-dCMP would be converted to aza-dUMP. However, very little is known about the activities of aza-dUMP and its metabolites.

Thymidylate synthase methylates the 5 carbon of dUMP, and inhibition of this enzyme by 5-fluoro-2'-deoxyuridine-5'-monophosphate results in cytotoxicity due to depression of TTP levels and incorporation of uracil and/or 5-fluorouracil into DNA (Parker and Cheng, 1990). Therefore, it is possible that the 5-aza-moiety could inhibit the methylation of aza-dUMP by thymidylate synthase in a manner similar to that of aza-cytosine and DNMT1. Recently, a compound screen of 11,000 compounds in intact cells using a cellular thermal shift assay identified aza-dUMP as an inhibitor of thymidylate synthase (Almqvist et al., 2016). In other studies (Reguena et al., 2016) the toxicity of aza-dCyd was enhanced in cells deficient in dUTPase activity, which was correlated with increased intracellular levels of dUTP (and/or aza-dUTP) and incorporation of uracil into DNA. More recently in in vitro and in vivo experiments treatment with aza-dCyd resulted in the depletion of thymidylate synthase (Gu et al., 2020). These three studies suggest that sufficient aza-dUMP is produced in cells and that this compound inhibits thymidylate synthase resulting in the decrease of TTP levels and accumulation of dUTP and aza-dUTP. The removal of uracil or aza-uracil from DNA by uracil DNA glycosylase results in a futile cycle of incorporation and removal that overwhelms DNA repair mechanisms.

Early studies have shown that aza-dCyd can cause alkali-labile breaks in DNA (D’Incalci et al., 1985; Covey et al., 1986), which are caused by a saturable (enzymatic) DNA repair mechanism (Limonta et al., 1993). It was proposed in this work that the toxicity of aza-dCyd was due to the removal of 5-azacytosine from DNA by DNA glycosylases leading to the formation of
apyrimidinic sites, and the excessive incorporation and removal of aza-dCyd sets up a futile cycle that overwhelms the DNA repair process causing DNA damage. These studies suggest that there is a balance between the amount of aza-dCyd that is incorporated into DNA that is necessary for depletion of DNMT1 and the amount incorporated that results in toxicity. Based on the more recent studies (Almqvist et al., 2016; Reguena et al., 2016; Gu et al., 2020), it is possible that the DNA damage reported in these studies was due to the incorporation of dUTP or aza-dUTP.

No studies have been reported that evaluate aza-dUrd as a substrate for dThd kinase, so it is not known whether or not aza-dUMP can be formed from aza-dUrd. However, aza-dUrd is a substrate for dThd phosphorylase (Cihak and Vesely, 1978; Cihak, 1978), which is expressed throughout the body, and therefore, a considerable amount of 5-aza-uracil should also circulate after exposure to aza-dCyd. Early studies with aza-dCyd indicated that 5-aza-uracil is activated and incorporated into RNA (Cihak and Sorm, 1972), which could also contribute to the toxicity of aza-dCyd. Although generation of aza-uracil may not contribute to aza-dCyd activity in vitro, it may be very important in vivo since most of the administered drug is deaminated to aza-dUrd.

Unfortunately, no studies have been conducted to evaluate the metabolism of aza-T-dCyd. However, since treatment with aza-T-dCyd results in the depletion of DNMT1, it is clear that it is readily converted to aza-T-dCTP and incorporated into DNA. Furthermore, if one assumes that the 4’-thio moiety of aza-T-dCyd affects its metabolism in a similar manner as that seen with T-dCyd, then one would predict that the metabolism of aza-T-dCyd (Figure 6) would be very different than that of aza-dCyd (Figure 5), and that little aza-T-dCyd would be converted to either aza-T-dUMP or aza-uracil. If true, then this difference in metabolism could explain the large therapeutic index of aza-T-dCyd (depletion of DNMT1 vs toxicity) relative to aza-dCyd (Table 1). Because of a potential difference in activity of dCMP deaminase with these two
agents, it is possible that the primary intracellular metabolite of aza-dCyd in cells after activation by dCyd kinase is aza-dUMP, whereas for aza-T-dCyd it is aza-T-dCTP. Differences in how these molecules interact with DNA polymerases and influence DNA function could also explain the difference observed in their therapeutic indices. As discussed above some studies have indicated that the toxicity of aza-dCyd is due to DNA damage caused by the incorporation of aza-dCyd (Limonta et al., 1993) or aza-dUrd (Reguena et al., 2016) and their subsequent removal by DNA glycosylases. Others have shown that 4'-thio-2'-deoxyuridine is not able to inhibit uracil DNA glycosylase (Verri et al., 2000), which suggests that 4'-thio nucleosides in DNA would not be substrates for DNA glycosylases. Therefore, it is possible that aza-T-dCyd residues in DNA are not recognized by DNA glycosylases, and that a futile cycle of incorporation/removal does not occur with aza-T-dCyd resulting in less DNA damage.

Conclusion

Aza-T-dCyd has two important attributes (oral bioavailability and lower toxicity) that distinguish it from aza-dCyd and argue strongly for its evaluation in various disease settings where selective depletion of DNMT1 is considered to be a rational strategy (Figure 7). The reason for these differences is not known at present. Without a complete understanding of how these molecules are metabolized in cells as well as the effect of their metabolites on various enzymatic targets, it is not productive to speculate too much about how the mechanism of action of these two compounds differ. It will be necessary to determine the kinetic constants of aza-T-dCyd and aza-dCyd with dCyd kinase and Cyd deaminase, as well as how their metabolites interact with various enzymes involved in nucleotide metabolism: such as DNA polymerases, dCMP deaminase, and thymidylate synthase. That said, knowledge from studies with other 4'-thio molecules suggest significant differences in the metabolism of these two compounds could explain the relatively low toxicity of aza-T-dCyd. In addition, the fact that aza-T-dCyd has high
oral bioavailability and does not need THU as a combination partner suggests that aza-T-dCyd may be a poor substrate for cytidine deaminase.

Although both aza-Cyd and aza-dCyd are approved for the treatment of some diseases, there is no strong evidence that depletion of DNMT1 is primarily responsible for their clinical activity. Both aza-dCyd and aza-Cyd are currently administered for short periods with significant toxicity followed by long recovery period. Because depletion of DNMT1 is not expected to cause acute toxicity, it is likely that their clinical activity is due to inhibition of enzymes other than DNMT1. Regardless, the therapeutic index for aza-dCyd seems to be very narrow and the larger therapeutic index of aza-T-dCyd in mice suggests that it would be a better candidate to selectively deplete DNMT1 from cells and determine in humans whether or not depletion of DNMT1 is an effective target for these various diseases. Our in vivo results in murine models of cancer indicate that mice can be treated on an extended schedule with aza-T-dCyd at an effective DNMT1 depleting dose without toxicity, which would allow for treatment of all target cells as they enter S phase.
Authorship Contributions

Participated in research design: Parker, Thottassery

Conducted experiments: Parker, Thottassery

Performed data analysis: Parker, Thottassery

Wrote or contributed to the writing of the manuscript: Parker, Thottassery

Financial Disclosures

No author has an actual or perceived conflict of interest with the contents of this article
References


Gu X, Tohme R, Tomlinson B, Sakre N, Hasipek M, Durkin L, Schuerger C, Grabowski D, Zidan AM, Radivoyevitch T, Hong C, Carraway H, Hamilton B, Sobecks R, Patel B, Jha BK, His ED,


Huang KC, Chiang SF, Chen WT, Chen TW, Hu CH, Yang PC, Ke TW, Chao KSC (2020) Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer. *Cancers (Basel)* **12**: 462


**Footnotes**

This work was supported by the Alabama Drug Discovery alliance and the University of Alabama Center for Clinical and Translational Science [5UL1 RR025777] and the National Institutes of Health, National Cancer Institute [grant CA34200 and contract N01-CO-12400]. This research was supported in part by the Intramural Research Program of the National Institutes of Health [National Cancer Institute].
Table 1

Toxicity and DNMT1 depletion in CEM tumor xenografts in mice post treatment with either aza-T-dCyd or aza-dCyd.

<table>
<thead>
<tr>
<th>Dose (mg/kg x 9)</th>
<th>aza-T-dCyd</th>
<th>aza-dCyd</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DNMT1</td>
<td>Death</td>
</tr>
<tr>
<td>5</td>
<td>ND</td>
<td>no</td>
</tr>
<tr>
<td>2.5</td>
<td>ND</td>
<td>no</td>
</tr>
<tr>
<td>1.2</td>
<td>ND</td>
<td>no</td>
</tr>
<tr>
<td>0.6</td>
<td>ND</td>
<td>no</td>
</tr>
<tr>
<td>0.3</td>
<td>±</td>
<td>no</td>
</tr>
</tbody>
</table>

ND, DNMT1 not detected; ±, DNMT1 barely detected

Mice bearing CEM tumor xenografts were treated daily for 9 days with either aza-T-dCyd or aza-dCyd (0.3 to 5 mg/kg per dose). At death of animal or day 10 tumors were removed and evaluated for DNMT1 (Thottassery et al., 2014).
Figure Legends

Figure 1 Structures of aza-Cyd, aza-dCyd, zebularine, F-dCyd, T-dCyd, and aza-T-dCyd

Figure 2 Metabolism of dCyd in human cells.

Figure 3 Metabolism of T-dCyd in CEM and HCT-116 cells
Dashed lines indicate little, if any, enzymatic activity.

Figure 4 Effect of aza-T-dCyd and aza-dCyd on tumor growth and DMNT1 levels in CEM tumor xenografts.

Mice bearing CEM tumor xenografts were treated daily for 9 days with either 1 mg/kg aza-T-dCyd or 0.5 mg/kg aza-dCyd. Treatment with 0.5 mg/kg aza-dCyd daily for 9 days resulted in the death of all mice. After a 3-day rest period aza-T-dCyd treatment was resumed for another 20 days. At the end of the 20-day treatment period the mice were sacrificed and DNMT1 levels in tumor were determined.

Figure 5 Metabolism of aza-dCyd in human cells

Figure 6 Potential metabolism and mechanism of action of aza-T-dCyd in human cells

Figure 7 Pharmacodynamic similarities and differences between aza-T-dCyd and aza-dCyd.

“-“ indicates little if any enzymatic activity.

“+++” indicates good enzymatic activity.

“?” indicates enzymatic activity unknown.
Figure 2
Figure 3

CEM cells

DNA

\[ \text{T-dCTP} \]

100%

\[ \text{dCMP deaminase} \]

\[ \text{T-dCMP} \rightarrow \text{T-dUMP} \]

\[ \text{thymidylate synthase} \]

\[ \text{T-dTMP} \]

\[ \text{dCyd kinase} \]

\[ \text{T-dCyd} \]

HCT-116 cells

DNA

\[ \text{T-dCTP} \]

10%

\[ \text{dCMP deaminase} \]

\[ \text{T-dCMP} \rightarrow \text{T-dUMP} \]

\[ \text{thymidylate synthase} \]

\[ \text{T-dTMP} \]

\[ \text{dCyd kinase} \]

\[ \text{T-dCyd} \]

90%

\[ \text{dThd phosphorylase} \]

\[ \text{T-dUrde} \rightarrow \text{uracil} \]
Figure 4

There was no DNMT1 in these tumors.

[Graph showing median tumor weight over days post implant for different treatment groups: vehicle, aza-dCyd, 0.5 mg/kg x 9, aza-T-dCyd, 1 mg/kg daily.]

[Western blot images showing protein expression for DNMT1 and GAPDH under Vehicle and aza-T-dCyd conditions.]
Figure 7

**Pharmacodynamic similarities and differences between aza-T-dCyd and aza-dCyd**

<table>
<thead>
<tr>
<th></th>
<th>aza-T-dCyd</th>
<th>aza-dCyd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depletion of DNMT1</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Therapeutic Index</td>
<td>high</td>
<td>low</td>
</tr>
<tr>
<td>Oral bioavailability</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>Need for THU</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Chemical stability (half-life at pH 6.7)</td>
<td>45 hrs</td>
<td>13 hrs</td>
</tr>
</tbody>
</table>

**Important metabolic differences:**

- Cytidine deaminase: ? +++
- Thymidine phosphorylase: - +++
- dCMP deaminase: - +++
- Thymidine kinase: - ?